Abstract.
Whole-cell patch-clamp recordings were made from macrophages derived from human monocytes that had been cultured for 5–7 days. The P2X agonists ATP (100 µM) and 2′,3′-(4-benzoyl)-benzoyl ATP (BzATP, 100 µM) induced inward currents. A second application of the agonists was characterized by strong desensitisation of the maximum current. Pyridoxal phosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS), a non-specific P2X antagonist, and 1-(N,O-bis[5-isoquinolinesulphonyl]-N-methyl-L-tyrosyl)-4-phenylpiperazine (KN62), a potent P2X7 antagonist at the human receptor, both reduced the ATP-induced inward current. KN62 also inhibited the BzATP-induced current. The P2X7 antagonist Coomassie Brilliant Blue G (BBG), believed to be potent at the human but even more so potent at the rat receptor, did not reduce the BzATP-induced inward current significantly. These results indicate that the native P2X7 receptor subtype is expressed in human macrophages and that this receptor subtype is involved in the ATP-mediated inward current. Our experiments suggest that other P2X receptors also appear to be involved in the ATP-mediated current in human monocyte-derived macrophages.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Eschke, D., Wüst, M., Hauschildt, S. et al. Pharmacological characterization of the P2X7 receptor on human macrophages using the patch-clamp technique. Naunyn-Schmied Arch Pharmacol 365, 168–171 (2002). https://doi.org/10.1007/s00210-001-0501-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00210-001-0501-2